proteolix.com Revenue and Competitors
Estimated Revenue & Valuation
- proteolix.com's estimated annual revenue is currently $2.5M per year.
- proteolix.com's estimated revenue per employee is $155,000
Employee Data
- proteolix.com has 16 Employees.
- proteolix.com grew their employee count by 0% last year.
proteolix.com's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | VP Research | Reveal Email/Phone |
3 | Associate Director | Reveal Email/Phone |
proteolix.com Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is proteolix.com?
Not sure what to write? Check out your company's website.Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in multiple types of cancer, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is headquartered in South San Francisco.
keywords:N/A
N/A
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
proteolix.com News
... professor of chemistry and pharmacology and founder of Proteolix Inc. Craig Crews and ENT surgeon at Harvard Medical School and lecturer...